Skip to main content
SpringerLink
Log in

Belimumab: A Guide to Its Use in Systemic Lupus Erythematosus

  • Adis Drug Clinical Q&A
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Belimumab (Benlysta ®), a fully human recombinant IgG1λ monoclonal antibody that inhibits the binding of soluble B lymphocyte stimulator to B cells, is indicated for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity despite receiving standard therapy. In multinational trials, significantly more belimumab recipients than placebo recipients achieved an SLE Responder Index response at 52 weeks.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Table III
Fig. 2

Similar content being viewed by others

References

  1. Crispin JC, Liossis S-NC, Kis-Toth K, et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 2010; 16(2): 47–57

    Article  PubMed  CAS  Google Scholar 

  2. Cancro MP, D’Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009 May; 119(5): 1066–73

    Article  PubMed  CAS  Google Scholar 

  3. The American College of Rheumatology. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum 1999 Sep; 42(9): 1785–96

    Article  Google Scholar 

  4. Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003 Nov; 48(11): 3253–65

    Article  PubMed  CAS  Google Scholar 

  5. Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008 Sep; 10(5): R109

    Article  PubMed  Google Scholar 

  6. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009 Sep 15; 61(9): 1168–78

    Article  PubMed  CAS  Google Scholar 

  7. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011 Dec; 63(12): 3918–30

    Article  PubMed  CAS  Google Scholar 

  8. Benlysta (belimumab): summary of product characteristics. London: European Medicines Agency, 2011 Aug 9

  9. Benlysta ® (belimumab) for injection, for intravenous use only: US prescribing information. Rockville (MD): Human Genome Sciences, 2011 Mar

  10. Benlysta™ (belimumab lyophilized powder for intravenous infusion): Canadian product monograph. Mississauga (ON): GlaxoSmithKline Inc., 2011 Jul 6

  11. Burness CB, McCormack PL. Belimumab: in systemic lupus erythematosus. Drugs 2011; 71(18): 2435–44

    Article  PubMed  CAS  Google Scholar 

  12. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011 Feb 26; 377(9767): 721–31

    Article  PubMed  CAS  Google Scholar 

  13. Human Genome Sciences. Arthritis Advisory Committee Meeting briefing document for the 16 November 2010 meeting [online]. Available from URL: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisDrugsAdvisoryCommittee/UCM233581.pdf [Accessed 2011 Nov 11]

  14. Food and Drug Administration (FDA). Briefing document for the Arthritis Advisory Committee meeting: November 16, 2010 [online]. Available from URL: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisdrugsadvisorycommittee/ucm233579.pdf [Accessed 2011 Nov 11]

  15. Cervera R, Furie R, Levy R, et al. Relationship of belimumab treatment response with corticosteroid use and severe flares in patients with SLE: Bliss-52 and Bliss-76 [abstract no. THU0430]. 12th Annual Congress of the European League Against Rheumatism; 2011 May 25–28; London

    Google Scholar 

  16. Wallace DJ, Navarra S, Gallacher A, et al. Safety profile of belimumab, a BLyS-specific inhibitor, in patients with active systemic lupus erythematosus (SLE): pooled data from phase 2 and 3 studies [abstract no. 1172]. 74th Annual Scientific Meeting of the American College of Rheumatology and the 45th Annual Meeting of the Association of Rheumatology and Health Professionals; 2010 Nov 6–11; Atlanta (GA)

    Google Scholar 

  17. Merrill JT, Furie RA, Wallace DJ, et al. Sustained disease improvement and safety profile over the 1500 patient-year experience (6 years) with belimumab in patients with systemic lupus erythematosus [abstract no. 584]. 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology Health Professionals; 2011 Nov 4–9; Chicago (IL)

    Google Scholar 

Download references

Acknowledgments and Disclosures

This article was adapted from Drugs 2011; 71 (18): 2435-44,[11] and was reviewed by: R. Cervera, Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain; M.A. Khamashta, Lupus Research Unit, the Rayne Institute, St Thomas Hospital, London, United Kingdom.

The preparation of this article was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the articles. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Lesley J. Scott, Celeste B. Burness & Paul L. McCormack

Authors
  1. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Celeste B. Burness
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul L. McCormack
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lesley J. Scott.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scott, L.J., Burness, C.B. & McCormack, P.L. Belimumab: A Guide to Its Use in Systemic Lupus Erythematosus. BioDrugs 26, 195–199 (2012). https://doi.org/10.2165/11209060-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11209060-000000000-00000

Keywords

Search

Navigation